IS7252A - Fenýl setin tríasól og notkun þeirra sem kjörvísir hindrar af ALk5 kínasa - Google Patents

Fenýl setin tríasól og notkun þeirra sem kjörvísir hindrar af ALk5 kínasa

Info

Publication number
IS7252A
IS7252A IS7252A IS7252A IS7252A IS 7252 A IS7252 A IS 7252A IS 7252 A IS7252 A IS 7252A IS 7252 A IS7252 A IS 7252A IS 7252 A IS7252 A IS 7252A
Authority
IS
Iceland
Prior art keywords
inhibitor
indicator
phenyl substituted
substituted triazole
alk5 kinase
Prior art date
Application number
IS7252A
Other languages
English (en)
Inventor
Mary Gaster Laramie
Paul Heer Jag
Daniel Heightman Thomas
Hele Payne Andrew
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of IS7252A publication Critical patent/IS7252A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IS7252A 2001-11-15 2004-05-06 Fenýl setin tríasól og notkun þeirra sem kjörvísir hindrar af ALk5 kínasa IS7252A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0127430.7A GB0127430D0 (en) 2001-11-15 2001-11-15 Compounds
PCT/EP2002/013482 WO2003042211A1 (en) 2001-11-15 2002-11-14 Phenyl substituted triazoles and their use as selective inhibors of akl5 kinase

Publications (1)

Publication Number Publication Date
IS7252A true IS7252A (is) 2004-05-06

Family

ID=9925832

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7252A IS7252A (is) 2001-11-15 2004-05-06 Fenýl setin tríasól og notkun þeirra sem kjörvísir hindrar af ALk5 kínasa

Country Status (17)

Country Link
US (1) US20050014938A1 (is)
EP (1) EP1444232A1 (is)
JP (1) JP2005518352A (is)
KR (1) KR20050044476A (is)
CN (1) CN1608065A (is)
BR (1) BR0214160A (is)
CA (1) CA2467267A1 (is)
GB (1) GB0127430D0 (is)
HU (1) HUP0402227A2 (is)
IL (1) IL161852A0 (is)
IS (1) IS7252A (is)
MX (1) MXPA04004593A (is)
NO (1) NO20042244L (is)
PL (1) PL369605A1 (is)
RU (1) RU2004117862A (is)
WO (1) WO2003042211A1 (is)
ZA (1) ZA200403487B (is)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003224335A1 (en) * 2002-05-15 2003-12-02 Smithkline Beecham Corporation Benzoxazine and benzoxazinone substituted triazoles
GB0217780D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
GB0217787D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd C ompounds
AU2003256297A1 (en) * 2002-08-09 2004-02-25 Eli Lilly And Company Benzimidazoles and benzothiazoles as inhibitors of map kinase
US7901874B2 (en) 2003-09-11 2011-03-08 Hubit Genomix, Inc. Methods for identifying agents for preventing or treating proliferative diseases, and for inhibiting extracellular matrix or α1 type IV collagen
WO2005080380A1 (en) * 2004-02-03 2005-09-01 Eli Lilly And Company Kinase inhibitors
JP2008508314A (ja) * 2004-07-28 2008-03-21 アイアールエム・リミテッド・ライアビリティ・カンパニー ステロイドホルモン核内受容体のモジュレーターとしての化合物および組成物
EP1869037B1 (en) * 2005-03-25 2011-07-27 Tibotec Pharmaceuticals Heterobicylic inhibitors of hvc
AR056347A1 (es) 2005-05-12 2007-10-03 Tibotec Pharm Ltd Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas
DE102005061840A1 (de) 2005-12-23 2007-06-28 Merck Patent Gmbh Triazolderivate
DK2044025T3 (da) 2006-06-30 2013-01-14 Novartis Ag Quinolinonderivater samt farmaceutiske sammensætninger deraf
EP2097084B1 (en) 2006-10-04 2015-01-28 Janssen R&D Ireland Carboxamide 4-[(4-pyridyl)amino] pyrimidines for the treatment of hepatitis c
EP1921072A1 (en) * 2006-11-10 2008-05-14 Laboratorios del Dr. Esteve S.A. 1,2,3-Triazole derivatives as cannabinoid-receptor modulators
US7678819B2 (en) * 2006-12-07 2010-03-16 The Trustees Of The University Of Pennsylvania Acetylene derivatives and their use for binding and imaging amyloid plaques
KR101076628B1 (ko) 2008-07-09 2011-10-27 포항공과대학교 산학협력단 불균일 구리 나노 촉매 및 그 제조방법
WO2010005127A2 (en) * 2008-07-09 2010-01-14 Postech Academy-Industry Foundation Heterogeneous copper nanocatalyst and manufacturing methods thereof
US8586581B2 (en) * 2009-12-17 2013-11-19 Hoffmann-La Roche Inc Ethynyl compounds useful for treatment of CNS disorders
CN102443009B (zh) * 2010-09-30 2014-04-16 山东轩竹医药科技有限公司 并环激酶抑制剂
DK2855665T3 (da) 2012-05-30 2019-11-04 Univ Cornell Tilvejebringelse af funktionelle og bestandige endotele celler fra humane amnionvæske-afledte celler
CA2914615C (en) 2013-06-05 2023-10-17 Biotime, Inc. Compositions and methods for induced tissue regeneration in mammalian species
US11078462B2 (en) 2014-02-18 2021-08-03 ReCyte Therapeutics, Inc. Perivascular stromal cells from primate pluripotent stem cells
US10240127B2 (en) 2014-07-03 2019-03-26 ReCyte Therapeutics, Inc. Exosomes from clonal progenitor cells
CN108779435B (zh) 2015-12-07 2022-05-03 再生疗法有限公司 用于重新衍生不同的多能干细胞衍生的褐色脂肪细胞的方法
WO2022251359A1 (en) * 2021-05-26 2022-12-01 Theravance Biopharma R&D Ip, Llc Bicyclic inhibitors of alk5 and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1112070B1 (en) * 1998-08-20 2004-05-12 Smithkline Beecham Corporation Novel substituted triazole compounds
JP2002541253A (ja) * 1999-04-09 2002-12-03 スミスクライン・ビーチャム・コーポレイション トリアリールイミダゾール
CO5271680A1 (es) * 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
GB0007405D0 (en) * 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
AU2001253418A1 (en) * 2000-04-12 2001-10-30 Smith Kline Beecham Corporation Compounds and methods
GB0027987D0 (en) * 2000-11-16 2001-01-03 Smithkline Beecham Plc Compounds

Also Published As

Publication number Publication date
EP1444232A1 (en) 2004-08-11
CA2467267A1 (en) 2003-05-22
CN1608065A (zh) 2005-04-20
JP2005518352A (ja) 2005-06-23
PL369605A1 (en) 2005-05-02
NO20042244L (no) 2004-07-13
IL161852A0 (en) 2005-11-20
US20050014938A1 (en) 2005-01-20
KR20050044476A (ko) 2005-05-12
MXPA04004593A (es) 2004-08-13
BR0214160A (pt) 2004-09-28
HUP0402227A2 (hu) 2005-02-28
ZA200403487B (en) 2006-05-31
RU2004117862A (ru) 2006-01-10
GB0127430D0 (en) 2002-01-09
WO2003042211A1 (en) 2003-05-22

Similar Documents

Publication Publication Date Title
CY2015028I2 (el) Ενας αναστολεας ν-ακυλοσφιγγοσινο γλυκοζυλοτρανσφερασης
DE60203995D1 (de) Triazoloverbindungen als mmp-inhibitoren
ATE505471T1 (de) Azaindol-kinaseinhibitoren
NO20034308D0 (no) Nye tyrokinase-inhibitorer
DE60234125D1 (de) E inhibitoren
DE60208661D1 (de) Diaminothiazole und ihre verwendung als cyclinabhängige kinase inhibitoren
ATE452891T1 (de) Pyrimidopyrimidone als kinaseinhibitoren
NO20050636L (no) Inhibitorer av tyrosinkinaser
ATE339419T1 (de) Pyrazolenthaltende zusammensetzungen und ihre verwendung als gsk-3 inhibitoren
ATE370938T1 (de) Pro-pharmakon von cox-2-inhibitoren
NO20041293D0 (no) Alkyn-aryl-fosfodiesterase-4-inhibitorer
ATE286049T1 (de) Pyridazinonaldose reductase inhibitoren
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
DE60230934D1 (de) Fab-i-inhibitoren
PT1370553E (pt) Inibidores de rhoquinase
AR028253A1 (es) Inhibidores de la glucogeno fosforilasa
IL161852A0 (en) Phenyl substituted triazoles and their use as selective inhibitors of akl5 kinase
IS6788A (is) Sölt af ísóþíasól-4-karboxamíði og notkun þeirra sem efnisþættir gegn offjölgun (proliferation)
EP1534268A4 (en) TYROSINE KINASE INHIBITORS
ITMI20011061A0 (it) Composizioni fluoroelastomeriche
ITMI20011060A0 (it) Composizioni fluoroelastomeriche
FI20010558A0 (fi) Kappaleiden paikannus
NO20040996L (no) Nye forbindelser og sammensetninger som catepsin-inhibitorer
DE60231897D1 (de) Triazol derivate als cyclooxygenase inhibitoren
DE60203120D1 (de) Imidazopyridinone als p38 map kinase inhibitoren